Sign inJoin waitlistJoin the waitlist

Ayalew Tefferi

Professor of Medicine · Mayo Clinic College of Medicine and Science

Credentials: · · · ·

History

Mayo Clinic College of Medicine and Science
Present

Mayo Clinic College of Medicine and Science
1988–1989
Mayo Clinic College of Medicine and Science
1985–1988
Catholic Health Services/St Joseph Hospital
1982–1985
- Medicine University of Athens Medical School
1978–1982

Research

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Review · Blood · 2009 · 3,446 citations
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood · 2022 · 2,489 citations
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Cancer Cell · 2005 · 2,411 citations

Animesh Pardanani
442 papers
Naseema Gangat
372 papers · 16 as a fellow
Mrinal Patnaik
235 papers · 4 as a fellow
Curtis Hanson
215 papers
Rhett Ketterling
183 papers
Mark Litzow
161 papers
Kebede Begna
154 papers
Aref Al-Kali
145 papers · 7 as a fellow
William Hogan
114 papers · 1 as a fellow
Michelle Elliott
110 papers · 4 as a fellow
Ruben Mesa
110 papers · 24 as a resident
Abhishek Mangaonkar
92 papers · 6 as a fellow

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $20.1K · Mayo Clinic Rochester
1998–1999

Clinical trials

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Principal investigator · Completed · Phase 1, Phase 2
Incyte Corporation
2007–2017
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Study chair · Completed · Phase 2
Sierra Oncology LLC - a GSK company
2010–2014
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Study chair · Completed · Phase 1, Phase 2
Sierra Oncology LLC - a GSK company
2009–2012
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
Study chair · Completed · Phase 1, Phase 2
Bristol-Myers Squibb
2008–2014